

# Arcadia Biosciences Inc

23:10 15 Mar 2019

## Arcadia Biosciences shares soar after FDA approves GLA safflower oil in cat food

Shares of Arcadia Biosciences Inc (NASDAQ:RKDA) rallied Friday after the US Food and Drug Administration approved its SONOVA gamma linolenic acid (GLA) safflower oil for use in cat food.

The oil, which is a concentrated source of GLA - an omega 6 fatty acid already used in nutritional supplements for humans - first got the green light from the FDA for use in canine diets back in 2017.

Investors applauded the FDA's move, sending Arcadia shares up 26% to \$8.83 before Friday's opening bell.

**READ:** Arcadia Biosciences shares soar on move into cannabis business  
"The FDA clearance of SONOVA GLA for use in cat food is another example of our proven ability to improve crops' nutrition and value as ingredients from concept to commercialization, as with our GoodWheat platform, said Raj Ketkar, Arcadia's CEO in a statement. "SONOVA GLA will allow cat and dog food formulators to respond to consumer demand for natural, plant-based oils as wellness ingredients for their beloved companions."

In pets, the benefits of GLA include reducing inflammation, improving metabolism, boosting the immune system and improving the health and shine of skin and coats. GLA is found in only a handful of plant-based oils, such as evening primrose oil and borage oil, which contain about 10% and 20% GLA respectively.

**READ:** Arcadia Biosciences shares pop after receiving industrial hemp license in Hawaii

By comparison, SONOVA, which is the end-product of crop improvement by Arcadia's scientists, contains 40% GLA, which makes it a particularly concentrated source of GLA.

SONOVA was introduced to the dog food market in the US in 2018 and has been used in dry dog and cat food formulas in Canada since 2015.

Based in Davis, California, Arcadia develops high-value food ingredients and nutritional oils that aim to meet the demand for healthier diets.

The company recently set up a unit, Arcadia Specialty Genomics, to focus on the genetic improvement of cannabis and hemp.

Contact Ellen Kelleher at [ellen@proactiveinvestors.com](mailto:ellen@proactiveinvestors.com)

**Price:** US\$3.64

**Market Cap:** US\$17.39M

### 1 Year Share Price Graph



June 2018 December 2018 June 2019

### Share Information

**Code:** RKDA

**Listing:** NASDAQ

**52 week High Low**  
**\$10.40 \$2.68**

**Sector:** Agribusiness

**Website:** [arcadiabio.com](http://arcadiabio.com)

### Company Synopsis:

*Arcadia Biosciences is a consumer-driven agricultural technology company that develops and commercializes high-value food ingredients, nutritional oils and products that help meet consumer demand for a healthier diet. Our GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace.*

### Author:

**Proactive Investors Australia**

**+61 (0)2 9280 0700**

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts

journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.